Kansamme parhaaksi : rotuhygienia Suomessa vuoden 1935 sterilointilakiin asti

Summary: In our nation's best interest : eugenics in Finland until the promulgation of the sterilization law of 1935

Vihollisia, vainoojia, syöpäläisiä : venäläisviha Suomessa 1917-1923

English summary: Foes, fiends and vermin : ethnic hatred of Russians in Finland 1917-1923

Harmaat aallot : ympäristönsuojelun tulo Suomeen

Simo Laakkonen

Elokuvatarkastuksen synty Suomessa (1907-1922)

Summary: Origins of preventive film control in Finland

Kun kumous vie kodin : Suomeen paenneet venäläiset 1917-1927

Marjo Haimila

Filmi poikki... : poliittinen elokuvasensuuri Suomessa 1939-1947

Summary: Cut! : political film censorship in Finland, 1939-1947

Arvostelusta näyttöön. Koulutuksen arvioinnin kehityspiirteitä Suomessa

Summary: From assessment to evaluation. Development of educational evaluation in Finland

Raakamaidon solupitoisuus Suomessa vuonna 1995

Osmo Myllykangas

Puoluevastainen mieliala Suomessa

Kyösti Pekonen

Sopimaton lasten kasvattajaksi! : opettajiin kohdistuneet poliittiset puhdistuspyrkimykset Suomessa 1944-1948

Summary: Unsuited to educate children! : attempted political purges of teachers in Finland from 1944-1948

Measurement of Bioactivity of Immunomodulatory Treatment of Relapsing Multiple Sclerosis. With Emphasis on MxA Protein

Background Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, which mainly affects young adults. In Finland, approximately 2500 out of 6000 MS patients have relapsing MS and are treated with disease modifying drugs (DMD): interferon- β (INF-β-1a or INF-β-1b) and glatiramer acetate (GA). Depending on the used IFN-β preparation, 2 % to 40 % of patients develop neutralizing antibodies (NAbs), which abolish the biological effects of IFN-β, leading to reduced clinical and MRI detected efficacy. According to the Finnish Current Care Guidelines and European Federation of Neurological Societis (EFNS) guidelines, it is suggested tomeasure the presence of NAbs during the first 24 months of IFN-β therapy. Aims The aim of this thesis was to measure the bioactivity of IFN-β therapy by focusing on the induction of MxA protein (myxovirus resistance protein A) and its correlation to neutralizing antibodies (NAb). A new MxA EIA assay was set up to offer an easier and rapid method for MxA protein detection in clinical practice. In addition, the tolerability and safety of GA were evaluated in patients who haddiscontinued IFN-β therapy due to side effects and lack of efficacy. Results NAbs developed towards the end of 12 months of treatment, and binding antibodies were detectable before or parallel with them. The titer of NAb correlated negatively with the amount of MxA protein and the mean values of preinjection MxA levels never returned to true baseline in NAb negative patients, but tended to drop in the NAb positive group. The test results between MxA EIA and flow cytometric analysis showed significant correlation. GA reduced the relapse rate and was a safe and well-tolerated therapy in IFN-β-intolerant MS patients. Conclusions NAbs inhibit the induction of MxA protein, which can be used as a surrogate marker of the bioactivity of IFN-β therapy. Compared to flow cytometricanalysis and NAb assay, MxA-EIA seemed to be a sensitive and more practical method in clinical use to measure the actual bioactivity of IFN-β treatment, which is of value also from a cost-effective perspective.

Jenkka and Jatsi, two new red raspberry cultivars

Selostus: Uudet suomalaiset vadelmalajikkeet Jenkka ja Jatsi

A simple culture system for time-lapse video recording of bovine embryos

Selostus: Yksinkertainen viljelymenetelmä naudan alkioiden aikaviivenauhoitusta varten

Non-surgical transfer of 4',6'-diamidino-2-phenylindole-stained equine embryos

Selostus: Hevosen alkioiden värjääminen DAPI:lla ennen vastaanottajaan siirtoa

Detection of bovine foetal DNA from amniotic fluid using the polymerase chain reaction

Selostus: Sikiön DNA:n tunnistaminen naudan sikiövedestä polymeraasiketjureaktion avulla